Uses of aldose-1-epimerase (mutarotase) for diagnosis and therapy of inflammatory diseases and sepsis
Uses of aldose 1-epimerase (SEQ ID NO:3) from body fluids or body tissues in human and veterinary medicine as a marker peptide for diagnosis, for prognosis of the course and for monitoring of the course of inflammations and infections and/or as a target for therapeutically influencing the course of inflammations and/or infections.
1. A method of differential early diagnosis and detection for the prognosis of, and therapy-accompanying assessment of the course of sepsis and severe infection in a patient in need thereof, the method comprising providing a biological fluid or a tissue sample from said patient, detecting and/or determining the presence and/or amount of human aldose 1-epimerase (A1E; SEQ ID #3) in the biological fluid or tissue sample from said patient, determining the presence, severity and course of the sepsis and severe infection, and evaluating the success of a therapy of the sepsis or severe infection in said patient.
2. The method according to claim 1 , wherein the method is an immunodiagnostic assay.
3. The method according to claim 1 , wherein the determination of human aldose 1-epimerase (A1E) is carried out indirectly as a determination of the associated A1E-mRNA or of the A1E enzyme activity.
4. The method according to claim 1 , wherein at least one further sepsis parameter is simultaneously determined and a measured result in the form of a set of at least two measured quantities, which is evaluated for fine diagnosis of sepsis, is obtained as part of a multiparameter determination.
5. The method according to claim 4 , wherein in the course of the multiparameter determination at least one further parameter is selected from the group consisting of procalcitonin, CA 19-9, CA 125, S100B, S100A proteins, soluble cytokeratin fragments, in particular CYFRA 21, TPS and/or soluble cytokeratin 1 fragments (sCY1F), the peptides inflaming and CHP, peptide prohormones, glycine N-acyltransferase (GNAT) and the C-reactive protein (CRP) is determined in addition to human aldose 1-epimerase.
6. The method according to claim 4 , wherein the multiparameter determination is carried out as a simultaneous determination by means of a chip technology measuring apparatus or an immunochromatographic measuring apparatus.
7. The method according to claim 6 , wherein the multiparameter determination obtained by means of the measuring apparatus is evaluated with the aid of a computer program.
8. The method according to claim 5 , wherein the multiparameter determination is carried out as a simultaneous determination by means of a chip technology measuring apparatus or an immunochromatographic measuring apparatus.